Find trials
Search tips

Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

Overview

About this study

The purpose of this study is to determine the extent to which PARP inhibitor (PARPi) treatment reduces systemic levels of mesenchymal stem cell (MSC)-derived cancer support factors in patients with cancer.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with ovarian cancer starting PARP inhibitor treatment.

Exclusion Criteria: 

  • Patients unwilling to return for blood draws.
  • Patients unwilling to continue PARP inhibitor treatment for at least one month.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Jacob Orme, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20547960

Mayo Clinic Footer